ASX:MSBBiotechs
Does Mesoblast’s New Board Leadership After First FDA Approval Change The Bull Case For ASX:MSB?
In early January 2026, Mesoblast Limited implemented a series of board changes, appointing Philip Facchina as non-executive Chair and Lyn Cobley as Chair of the Audit and Risk Committee, while former Chair Jane Bell retired from that role but remained on the board.
These governance shifts come as Mesoblast moves further into a revenue-generating commercial phase following its first U.S. FDA approval, highlighting an effort to align board oversight with the company’s next stage of corporate...